OneMedNet Inks Seven-Figure Multiyear Data Agreement with AI-Enabled Precision Medicine Partner

What happened

OneMedNet announced a seven-figure, multiyear agreement to supply de-identified, multimodal, longitudinal clinical real-world data to a partner that sells a derivative data solution. The partner is described as a "commercially scaled AI-enabled precision medicine company," signaling validation from an established player in the AI healthcare space. This represents a potentially significant contract relative to ONMD's FY2024 revenue of $643k and could provide a recurring revenue stream, though the exact dollar amount, payment schedule, and data delivery milestones have not been disclosed. The agreement fits squarely within ONMD's iRWD focus following the decommissioning of its legacy BEAM product, and it leverages the company's network of over 1,400 healthcare provider sites. While positive, the announcement alone does not address the company's acute liquidity constraints, going-concern warnings, or Nasdaq noncompliance, and investors should await evidence of actual revenue recognition and margin impact.

Implication

The seven-figure multiyear agreement provides early evidence of demand for ONMD's iRWD and could ease the company's pivot away from the discontinued BEAM product. However, with FY2024 revenue under $1 million and operating losses, a single contract—even if at the high end of seven figures—may not be transformative without additional bookings and successful delivery. The company's cash position of just $0.1 million plus $1.6 million in Bitcoin as of mid-2025, along with a going-concern note, means the agreement's upfront cash (if any) and timing will be critical for survival. Nasdaq compliance remains unresolved, and a reverse split or further dilutive financing could impair shareholder value despite growing revenue. Investors should monitor subsequent quarterly filings for iRWD revenue growth, gross margin trends, and any reduction in financing needs before upgrading the stock from a SELL.

Thesis delta

The prior SELL thesis centered on sub-scale revenue, liquidity risk, and lack of iRWD traction. This multiyear seven-figure agreement offers initial strategic validation and could support a shift to a cautious HOLD if revenue and cash flow improve over consecutive quarters. However, the fundamental overhangs of going-concern risk, Nasdaq noncompliance, and uncertain contract economics warrant maintaining a high degree of skepticism until financials confirm the deal's contribution.